3 Aug, 2021

Spago Nanomedical appoints Paul Hargreaves as Chief Development Officer

Spago Nanomedical AB (publ) announced today that Paul Hargreaves has been appointed Chief Development Officer (CDO), starting September 13. He will join the management team and have a key role in the clinical development of the company´s project portfolio.

The appointment of Paul Hargreaves as CDO marks an important step for Spago Nanomedical as the company continues to make progress with its unique project portfolio, with the Tumorad® candidate drug SN201 rapidly advancing towards clinical trials. This is an opportunity to provide potential treatment for advanced cancers of different origins.

Paul Hargreaves is a clinical pharmacologist with almost 30 years experience in clinical development in both the pharmaceutical and large CRO industry. At present, he serves as CDO with smaller Danish biotech companies, before that he held the position as Vice President, Head of Global Clinical Operations at LEO Pharma.

“We are very happy to have Paul joining Spago Nanomedical. His extensive experience from clinical development will become a valuable asset as we are progressing and rapidly coming into clinical phase with Tumorad®,” says CEO Mats Hansen.

”I´m excited to join Spago Nanomedical at a stage where the clinical development of the company´s projects accelerates. By means of Tumorad®, we can create opportunities for treatment of advanced cancers and eventually help patients in a way that is not possible today. I look forward to work with the group and take the company to the next level,” says Paul Hargreaves.

For further information, please contact Mats Hansen CEO Spago Nanomedical AB, +46 46 81188, mats.hansen@spagonanomedical.se.